Wedoany.com Report-Dec.4, AGC Biologics has entered a strategic partnership with ATUM to incorporate the Leap-In transposase expression platform into its Cell Line Development Centre of Excellence. The collaboration expands AGC Biologics' service offering and provides drug developers with access to ATUM's technology, which is designed to increase protein yields and shorten development timelines.

The partnership leverages cell engineering expertise to support antibody development for oncology, viral infection treatment, and immune modulation.

The Leap-In platform facilitates rapid and stable DNA integration into host cell genomes, enabling the generation of high-performing, genetically stable cell lines. On average, it reduces cell line development duration by approximately three months while delivering stable pools that reliably predict final clonal titres. This allows earlier initiation of analytical characterisation and process optimisation activities.

AGC Biologics Chief Technical Officer Kasper Møller stated: "We are acutely aware of the dual pressures our customers face: the need to innovate with increasingly complex molecules, and the simultaneous demand to get to the clinic faster and more cost-effectively than ever before. Our partnership with ATUM is a direct response to that need. We are not just adding a new technology; we are providing our customers with more options and flexibility. Our plan is to fully integrate the miCHO and Leap-In technologies and continue to optimise them, ensuring we can help our partners navigate their challenges and succeed."

The enhanced service portfolio now offers multiple cell line development pathways, enabling clients to select the most suitable approach based on molecular complexity, timeline requirements, and budget considerations. These services are available at AGC Biologics' facilities across Europe, Asia, and the United States.

The Leap-In integration particularly supports the development of therapeutic antibodies targeting oncology, viral infections, and immune system disorders, as well as other advanced biologics.

In May 2025, AGC Biologics announced a separate collaboration with Quell Therapeutics to advance multiple T-regulatory (Treg) cell therapy candidates for the treatment of serious immune-related conditions.

The partnership with ATUM strengthens AGC Biologics' position as a comprehensive CDMO partner capable of delivering flexible, high-efficiency solutions throughout the biologics development lifecycle.